Loading...

Mabion

WSE:MAB
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MAB
WSE
PLN1B
Market Cap
  1. Home
  2. PL
  3. Pharmaceuticals & Biotech
Company description

Mabion S.A., a biotechnology company, researches and develops biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases in Poland. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
MAB Share Price and Events
7 Day Returns
2.8%
WSE:MAB
0.9%
PL Biotechs
-0.9%
PL Market
1 Year Returns
-20%
WSE:MAB
-24.3%
PL Biotechs
-7.4%
PL Market
MAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mabion (MAB) 2.8% -13.5% 3.7% -20% -5.5% 41.9%
PL Biotechs 0.9% -9.6% -0.1% -24.3% -31.3% 5.5%
PL Market -0.9% -7.1% -6.3% -7.4% 9.6% -11.5%
1 Year Return vs Industry and Market
  • MAB outperformed the Biotechs industry which returned -24.3% over the past year.
  • MAB underperformed the Market in Poland which returned -7.4% over the past year.
Price Volatility
MAB
Industry
5yr Volatility vs Market

MAB Value

 Is Mabion undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mabion. This is due to cash flow or dividend data being unavailable. The share price is PLN73.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mabion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mabion's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:MAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in PLN PLN-5.26
WSE:MAB Share Price ** WSE (2019-05-20) in PLN PLN73.1
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 22.03x
Poland Market PE Ratio Median Figure of 463 Publicly-Listed Companies 10.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mabion.

WSE:MAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:MAB Share Price ÷ EPS (both in PLN)

= 73.1 ÷ -5.26

-13.89x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mabion is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Mabion is loss making, we can't compare the value of its earnings to the Poland market.
Price based on expected Growth
Does Mabion's expected growth come at a high price?
Raw Data
WSE:MAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.89x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.29x
Poland Market PEG Ratio Median Figure of 113 Publicly-Listed Companies 0.93x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mabion, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mabion's assets?
Raw Data
WSE:MAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in PLN PLN3.07
WSE:MAB Share Price * WSE (2019-05-20) in PLN PLN73.1
Poland Biotechs Industry PB Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 1.84x
Poland Market PB Ratio Median Figure of 689 Publicly-Listed Companies 0.97x
WSE:MAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:MAB Share Price ÷ Book Value per Share (both in PLN)

= 73.1 ÷ 3.07

23.8x

* Primary Listing of Mabion.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mabion is overvalued based on assets compared to the PL Biotechs industry average.
X
Value checks
We assess Mabion's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mabion has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MAB Future Performance

 How is Mabion expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mabion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mabion expected to grow at an attractive rate?
  • Unable to compare Mabion's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Mabion's earnings growth to the Poland market average as no estimate data is available.
  • Unable to compare Mabion's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:MAB Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.3%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10%
Poland Market Revenue Growth Rate Market Cap Weighted Average 5.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:MAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:MAB Future Estimates Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 140 1
2019-12-31 0 1
WSE:MAB Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-12-31 -39 -69
2018-09-30 -42 -72
2018-06-30 -62 -74
2018-03-31 -61 -59
2017-12-31 -54 -58
2017-09-30 -35 -56
2017-06-30 -24 -57
2017-03-31 -26 -59
2016-12-31 -15 -56
2016-09-30 0 -36 -77
2016-06-30 0 -44 -65
2016-03-31 3 -30 -51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Mabion is high growth as no earnings estimate data is available.
  • Unable to determine if Mabion is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:MAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Mabion Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:MAB Future Estimates Data
Date (Data in PLN Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
WSE:MAB Past Financials Data
Date (Data in PLN Millions) EPS *
2018-12-31 -5.26
2018-09-30 -5.41
2018-06-30 -6.08
2018-03-31 -5.02
2017-12-31 -4.91
2017-09-30 -4.75
2017-06-30 -4.85
2017-03-31 -4.99
2016-12-31 -4.84
2016-09-30 -6.36
2016-06-30 -5.75
2016-03-31 -4.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mabion will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Mabion's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Mabion's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Mabion's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Mabion's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mabion has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MAB Past Performance

  How has Mabion performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mabion's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mabion does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mabion's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mabion's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mabion's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mabion Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:MAB Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -68.87 20.39 44.93
2018-09-30 -71.57 23.43 47.54
2018-06-30 -73.70 23.37 48.59
2018-03-31 -59.39 22.44 41.30
2017-12-31 -57.89 20.80 43.26
2017-09-30 -56.03 17.60 43.36
2017-06-30 -57.24 16.02 46.77
2017-03-31 -58.57 14.55 47.29
2016-12-31 -55.83 13.39 44.22
2016-09-30 0.01 -76.61 10.69 71.39
2016-06-30 0.01 -64.51 9.05 58.63
2016-03-31 2.56 -51.25 7.60 47.55
2015-12-31 2.73 -42.54 5.18 39.78
2015-09-30 2.96 -5.85 3.56
2015-06-30 2.98 -4.68 2.85
2015-03-31 0.64 -5.16 1.70
2014-12-31 0.83 -4.46 1.40
2014-09-30 0.50 -4.40 4.28
2014-06-30 0.48 -4.08 4.17
2014-03-31 -0.10 -4.26 4.15
2013-12-31 0.01 -3.89 4.24
2013-09-30 -10.08 -3.49 2.06
2013-06-30 -8.60 -2.93 1.88
2013-03-31 0.01 -2.19 1.59
2012-12-31 0.89 -2.12 1.30
2012-09-30 5.69 -1.93 9.00
2012-06-30 8.40 -1.52 9.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mabion has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mabion has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mabion improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mabion's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mabion has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MAB Health

 How is Mabion's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mabion's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mabion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mabion's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mabion's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 12.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mabion Company Filings, last reported 4 months ago.

WSE:MAB Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 42.14 5.64 58.53
2018-09-30 58.01 5.68 67.99
2018-06-30 69.11 5.87 68.10
2018-03-31 -68.51 258.45 173.34
2017-12-31 -54.16 66.03 1.04
2017-09-30 -34.87 53.78 2.36
2017-06-30 -21.64 54.74 25.02
2017-03-31 -9.12 26.21 13.02
2016-12-31 3.73 12.72 14.83
2016-09-30 135.21 0.10 0.06
2016-06-30 137.11 0.14 0.92
2016-03-31 125.52 0.16 3.71
2015-12-31 45.46 0.23 6.07
2015-09-30 95.46 0.05 1.54
2015-06-30 97.80 0.06 0.05
2015-03-31 98.39 0.06 1.18
2014-12-31 99.78 0.10 6.95
2014-09-30 80.40 0.00 18.71
2014-06-30 81.58 0.00 17.62
2014-03-31 51.35 0.00 0.04
2013-12-31 52.06 0.00 3.61
2013-09-30 53.52 0.00 10.56
2013-06-30 54.37 0.00 31.78
2013-03-31 17.91 0.00 0.37
2012-12-31 18.24 0.02 4.50
2012-09-30 19.31 0.02 5.30
2012-06-30 19.60 0.02 1.30
  • Mabion's level of debt (13.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 13.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mabion has sufficient cash runway for 1.3 years based on current free cash flow.
  • Mabion has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 15% each year.
X
Financial health checks
We assess Mabion's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mabion has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MAB Dividends

 What is Mabion's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mabion dividends.
If you bought PLN2,000 of Mabion shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mabion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mabion's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:MAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Poland Market Average Dividend Yield Market Cap Weighted Average of 200 Stocks 4.1%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.5%
Poland Bottom 25% Dividend Yield 25th Percentile 2.8%
Poland Top 25% Dividend Yield 75th Percentile 7.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

WSE:MAB Future Dividends Estimate Data
Date (Data in PLN) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mabion has not reported any payouts.
  • Unable to verify if Mabion's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mabion's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mabion has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Mabion's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mabion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mabion has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MAB Management

 What is the CEO of Mabion's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Artur Chabowski
COMPENSATION PLN0
CEO Bio

Mr. Artur Chabowski served as Chairman-Supervisory Board at IFM Global Funds S.A. ( formerly known as Investment Fund Managers S.A.). Mr. Artur Chabowski served as the President of the Management Board at ACADIA since 2008. Mr. Chabowski serves as President of the Management Board at Mabion SA. Mr. Chabowski is a graduate of the Faculty of Organisation and Management at the Warsaw University of Technology. Mr. Chabowski completed post-graduate studies at the University of Princeton in the Woodrow Wilson School of Public & International Affairs.

CEO Compensation
  • Artur's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Artur's remuneration is higher than average for companies of similar size in Poland.
Management Team

Artur Chabowski

TITLE
President of the Management Board

Jaroslaw Walczak

TITLE
Member of the Management Board

Slawomir Jaros

TITLE
Director of Research & Development Department and Member of the Management Board

Grzegorz Grabowicz

TITLE
Member of Management Board
AGE
45
Board of Directors

Robert Aleksandrowicz

TITLE
Chairman of the Supervisory Board

Maciej Wieczorek

TITLE
Deputy Chairman of the Supervisory Board

Bogdan Manowski

TITLE
Vice Chairman of the Supervisory Board

Tadeusz Pietrucha

TITLE
Independent Member of the Supervisory Board

Grzegorz Stefanski

TITLE
Member of the Supervisory Board

Jacek Nowak

TITLE
Member of Supervisory Board

Tomasz Jasny

TITLE
Independent Member of the Supervisory Board
TENURE
3.9 yrs

Artur Olech

TITLE
Member of Supervisory Board

David James

TITLE
Member of Supervisory Board

Robert Konski

TITLE
Member of Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess Mabion's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mabion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MAB News

Simply Wall St News

Do Institutions Own Mabion S.A. (WSE:MAB) Shares?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of zł1.1b, Mabion is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Do Institutions Own Shares In Mabion SA (WSE:MAB)?

The big shareholder groups in Mabion SA (WSE:MAB) have power over the company. … With a market capitalization of zł1.4b, Mabion is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

An Intrinsic Calculation For Mabion SA (WSE:MAB) Shows It's 42.17% Undervalued

by taking the expected future cash flows and discounting them to their present value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Can Mabion SA. (WSE:MAB) Improve Your Portfolio Returns?

View our latest analysis for Mabion An interpretation of MAB's beta Mabion's beta of 0.22 indicates that the stock value will be less variable compared to the whole stock market. … MAB’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … As a result, this aspect of MAB indicates a higher beta than a similar size company with a lower portion of fixed assets on their balance sheet.

Simply Wall St -

Want To Invest In Mabion SA. (WSE:MAB)? Here's How It Performed Lately

After reading Mabion SA.'s (WSE:MAB) latest earnings update (30 September 2017), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … View our latest analysis for Mabion Were MAB's earnings stronger than its past performances and the industry? … Each year, for the past five years Mabion has seen an annual decline in revenue of -16.23%, on average.

Simply Wall St -

Investors Are Undervaluing Mabion SA. (WSE:MAB) By 40%

5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF (PLN, Millions) PLN115.15 PLN92.45 PLN129.20 PLN222.65 PLN161.15 Source Analyst x2 Analyst x2 Analyst x2 Analyst x2 Analyst x2 Present Value Discounted @ 8.35% PLN106.28 PLN78.75 PLN101.58 PLN161.56 PLN107.93 Present Value of 5-year Cash Flow (PVCF)= PLN556 The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = PLN161 × (1 + 1.7%) ÷ (8.3% – 1.7%) = PLN2,481 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = PLN2,481 / ( 1 + 8.3%)5 = PLN1,662 The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is PLN2,218. … WSE:MAB Intrinsic Value Mar 15th 18 Important assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

MAB Company Info

Description

Mabion S.A., a biotechnology company, researches and develops biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases in Poland. It develops MabionCD20, an oncology drug for the treatment of lymphomas and leukemia blood cancers, as well as rheumatoid arthritis; MabionHER2, an oncology drug for the treatment of breast cancer; and MabionVEGF_Fab, a drug for the treatment of various diseases resulting in vision impairment in adults. The company also develops MabionEGFR, an oncology drug for the treatment of metastatic colorectal cancer; and MabionVEGF, an oncology drug for the treatment of colon or rectal cancer, metastatic breast cancer, and metastatic or recurrent lung cancer with other anticancer drugs. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Details
Name: Mabion S.A.
MAB
Exchange: WSE
Founded: 2007
PLN1,002,988,433
13,720,772
Website: http://www.mabion.eu
Address: Mabion S.A.
gen. Mariana Langiewicza 60 street,
Konstantynów Lódzki,
95-050,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE MAB Common Bearer Shares Warsaw Stock Exchange PL PLN 10. Aug 2010
LSE 0QGW Common Bearer Shares London Stock Exchange GB PLN 10. Aug 2010
Number of employees
Current staff
Staff numbers
0
Mabion employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 21:37
End of day share price update: 2019/05/20 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/04/10
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.